Yoshihiro Sano, Shiomi Ohta, Hiroshi Ohkuma, Haruhumi Tsuge and Hidetoshi Arakawa
Posters: J Mol Biomark Diagn
Autistic spectrum disorder (ASD) is known as a disease of wide prevalence in children. DSM-IV is currently used as the diagnosis of ASD in clinical psychiatry. However, it is diffi cult to provide a defi nitive diagnosis of ASD. As the reason, characteristics of ASD are very similar to that of schizophrenia or social anxiety disorder. Th erefore, if children develop ASD until in early childhood and cannot be received treatment, they will have a high risk secondary disorder, depression etc. As a result, development of simple clinical laboratory test for ASD is necessary for early detection and rapid cure of that disorder. Recently, it has been suggested that ASD patients have low level of OXT in their plasma. Th erefore, OXT might be able to be used as one of the biomarker for ASD, psychiatric disorder. In this report, we developed highly sensitive bioluminescent enzyme immunoassay (BLEIA) for OXT utilizing the Luciferin/luciferase detection system. On this assay, the detection limit was 1 pg/assay (B0-3SD). Additionally, in the result of the cross reactivity examination, we conclude that BLEIA was developed high sensitively and specifi cally measurement for OXT. But it might not be able to measure of OXT in plasma of ASD patients, which is estimated to very low level. Finally, we will propose to the modifi cation of secondary antibody immobilized magnetic particles preparation, assay protocol and labeled antigen or re-selection of anti-OXT antibody, to contribute as clinical laboratory test for psychiatric disorder, ASD
Yoshihiro Sano has completed his Ph.D at the age of 28 years from Showa University. His work is development of high sensitive analytical method for peptide hormone etc, now.
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 